Skip to main content
. 2019 Aug 14;11(8):1175. doi: 10.3390/cancers11081175

Figure 6.

Figure 6

MTT assay cell viability of HepG2 cells treated with either SWCNTs, PX-866, or SWCNT/PX866 conjugates.